Mobosetinib (Anvili) instructions details and medication precautions

1. Introduction to drugs
Mobocertinib (trade name Exkivity) is an oral small molecule tyrosine kinase inhibitor (TKI) developed by Takeda Pharmaceuticals. It specifically targets non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins), a rare mutation type that is difficult to cover with traditional EGFR inhibitors. In 2021, the US FDA has accelerated approval of mobosetinib for adult patients with EGFR Exon20 insertion mutation-positive locally advanced or metastatic NSCLC who have progressed after previously receiving platinum-based chemotherapy.
2. Indications
The main indications for moboxetinib are:
Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with confirmed EGFR exon 20 insertion mutations, and the patient still has disease progression after receiving platinum-based chemotherapy.
There is no evidence that it is effective in patients with common EGFR-sensitive mutations (such as exon 19 deletion, L858R mutation), so it is not recommended for use in people with EGFR mutations other than Exon20ins.
3. Drug mechanism
Mobosetinib inhibits the growth and proliferation of tumor cells by selectively binding to and inhibiting the EGFR receptor containing Exon20 insertion mutations and blocking its downstream signaling pathways (such as RAS-RAF-MEK-ERK and PI3K-AKT). Compared with traditional EGFR-TKIs (such as erlotinib, gefitinib, and osimertinib), mobosetinib has a stronger affinity for Exon20 mutations, so it can cover this "resistant mutation subgroup."
4. Dosage and usage
1. Recommended dose: 160 mg, once daily, orally.
2. Administration method: Swallow the tablet whole. It is recommended to take it on an empty stomach (take the medicine 1 hour before or 2 hours after a meal). Avoid chewing or breaking it.
3. Treatment of missed doses: If you miss a dose and it is more than 6 hours before the next dose, you can take it immediately; if it is less than 6 hours, skip it and do not take it again.

4. Dose adjustment: If adverse reactions of grade 3 or above occur (such as severe diarrhea, QT interval prolongation, etc.), the dose can be gradually reduced to 120 mg or 80 mg once daily according to the instructions and doctor's evaluation.

5. Efficacy and clinical data
In the pivotal clinical trial EXCLAIM, mobosetinib showed:
Objective response rate (ORR): approximately 28%.
Disease control rate (DCR): approximately 78%.
Median progression-free survival (PFS): 7.3 months.
Median overall survival (OS): approximately 24 months.
This shows that moboxetinib has a clear clinical benefit for this type of patients and is one of the first oral targeted drugs targeting EGFR Exon20 mutations.
6. Adverse reactions
Common adverse reactions of moboxetinib include:
Gastrointestinal reactions: Diarrhea is the most common (up to more than 90%), some of which are severe diarrhea and require symptomatic antidiarrheal or dose adjustment.
Skin reactions: rash, dry skin, itching, etc.
Gastrointestinal symptoms: nausea, vomiting, decreased appetite.
Abnormal electrocardiogram: QT interval prolongation, which may cause arrhythmia.
Abnormal laboratory indicators: including elevated liver enzymes, elevated creatinine, and electrolyte disorders (such as low potassium and low magnesium).
Serious adverse events that require vigilance include: severe diarrhea, arrhythmia, interstitial pneumonia/pneumonia-like manifestations, etc.
7. Medication precautions
1. Prerequisites for genetic testing: Before using mobosetinib, the patient must be confirmed to have an EGFR Exon20 insertion mutation through a qualified testing method.
2. Cardiac monitoring: ECG and electrolytes (potassium, magnesium) should be monitored regularly before and during medication to prevent QT prolongation.
3. Diarrhea management: When diarrhea occurs, antidiarrheal drugs and fluid rehydration should be used promptly. If necessary, the medication should be suspended or the dosage should be reduced.
4. Liver function monitoring: Check liver function regularly and be alert to elevated transaminases.
5. Drug interactions: Avoid co-administration with strong CYP3A inhibitors or inducers to avoid affecting blood concentration.
6. Contraindicated during pregnancy and lactation: It may cause harm to the fetus or infant. Women should take reliable contraceptive measures during medication.
7. Elderly patients and patients with renal insufficiency: The dose needs to be adjusted or monitoring strengthened according to the doctor’s assessment.
8. Special Tips
Mobosetinib is a precision treatment drug for patients with specific mutations and is not suitable for all patients with non-small cell lung cancer.
Since the drug is not yet fully marketed in some countries and regions, and access is limited, patients should use the drug through formal channels under the guidance of a doctor.
Long-term efficacy and safety still need to be supported by more clinical data, but it brings new treatment hope to patients with EGFR Exon20 mutated NSCLC.
Mobosetinib is an oral targeted drug specifically targeting non-small cell lung cancer with EGFR Exon20 insertion mutations. The recommended dose is 160 mg once daily. Clinical trials have shown significant efficacy in previously treated patients, but are also associated with a high incidence of diarrhea, QT prolongation and laboratory abnormalities. During the medication period, genetic testing confirmation, electrocardiogram and electrolyte monitoring are required, and attention should be paid to drug interactions and adverse reaction management. For the target group, it provides a new precision treatment option, but it must be used rationally under the guidance of a professional doctor.
Reference link: https://www.drugs.com